Supplementary Table 1 -A pharmacovigilance study of terbinafine indication and liver enzyme elevation
Published: 7 July 2022| Version 1 | DOI: 10.17632/n8pkb4tzyz.1
Supplemental Table I. Reporting Numbers according to Age Group and Sex for Both FAERS and CVARO Databases. Details on patient demographics, notably age and sex, of patients reporting LEE events with terbinafine usage.